Compare noninvasive fibrosis scores from routine laboratory values. See thresholds, interpretations, trends, and downloadable reports. Built for fast reviews, teaching, audits, and counseling sessions.
Use routine lab values and metabolic inputs. The form stays single-column overall, while fields shift to 3, 2, and 1 columns across screen sizes.
This example uses routine inputs to show how multiple noninvasive scores can be reviewed together.
| Example Input | Value | Example Score Output | Value | Interpretation |
|---|---|---|---|---|
| Age | 52 years | FIB-4 | 3.993 | Higher risk |
| AST | 86 U/L | APRI | 1.536 | Higher risk |
| ALT | 64 U/L | NAFLD Fibrosis Score | 1.380 | Higher risk |
| Platelets | 140 ×109/L | BARD | 4 | Higher risk |
| AST ULN | 40 U/L | GUCI | 1.720 | Higher risk |
| BMI | 31.2 kg/m² | AST/ALT Ratio | 1.344 | Supportive marker |
| Albumin | 3.7 g/dL | Diabetes | Yes | Included in NFS and BARD |
| INR | 1.12 | Overall pattern | Several scores are elevated in this example. | |
All formulas below assume platelets are entered as ×109/L.
FIB-4 = (Age × AST) ÷ (Platelets × √ALT)
APRI = ((AST ÷ AST ULN) × 100) ÷ Platelets
NFS = -1.675 + (0.037 × Age) + (0.094 × BMI) + (1.13 × Diabetes/IFG) + (0.99 × AST/ALT) - (0.013 × Platelets) - (0.66 × Albumin)
BARD = 1 point if BMI ≥ 28, plus 2 points if AST/ALT ≥ 0.8, plus 1 point if diabetes or impaired fasting glucose is present.
GUCI = ((AST ÷ AST ULN) × INR × 100) ÷ Platelets
It estimates fibrosis risk using several noninvasive scoring systems derived from routine labs and metabolic inputs. It helps with triage and screening discussions, not diagnosis.
Each score emphasizes different variables and clinical contexts. Reviewing them together can reveal agreement, gray zones, or conflicting signals that deserve follow-up.
No. A high score raises concern but does not confirm cirrhosis. Imaging, elastography, biopsy, symptoms, and clinician review still matter.
APRI and GUCI normalize AST against the local laboratory upper limit. Different labs may use different reference ranges, so the threshold matters.
FIB-4 can overestimate risk in older adults. Age-adjusted thresholds improve interpretation and reduce false-positive concern in that group.
Yes. Some patients can have meaningful fibrosis even when AST or ALT are not dramatically elevated. Scores should be read with history and imaging.
Disagreement is common. In that situation, repeat labs, elastography, additional biomarkers, or specialist review may provide a clearer answer.
They save the entered inputs, calculated scores, interpretations, and overall summary so the current review can be shared or archived.
Important Note: All the Calculators listed in this site are for educational purpose only and we do not guarentee the accuracy of results. Please do consult with other sources as well.